Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Total Liabilities (2018 - 2025)

Dna X's Total Liabilities history spans 8 years, with the latest figure at $50.6 million for Q4 2025.

  • Quarterly results put Total Liabilities at $50.6 million for Q4 2025, up 11.41% from a year ago — trailing twelve months through Dec 2025 was $50.6 million (up 11.41% YoY), and the annual figure for FY2025 was $50.6 million, up 11.41%.
  • Total Liabilities for Q4 2025 was $50.6 million at Dna X, up from $40.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $50.6 million in Q4 2025 to a low of $21.3 million in Q1 2021.
  • The 5-year median for Total Liabilities is $31.6 million (2023), against an average of $32.2 million.
  • The sharpest move saw Total Liabilities decreased 28.99% in 2021, then soared 64.27% in 2025.
  • Year by year, Total Liabilities stood at $22.5 million in 2021, then soared by 49.78% to $33.6 million in 2022, then increased by 0.1% to $33.7 million in 2023, then soared by 34.93% to $45.4 million in 2024, then increased by 11.41% to $50.6 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $50.6 million, $40.9 million, and $37.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.